Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Average PT from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have received an average rating of “Buy” from the thirteen ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $89.90.

JANX has been the topic of a number of research reports. Stifel Nicolaus boosted their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $200.00 price target on shares of Janux Therapeutics in a report on Wednesday, December 11th. HC Wainwright lifted their price objective on shares of Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. UBS Group assumed coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price on the stock. Finally, BTIG Research raised their target price on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd.

Janux Therapeutics Stock Up 0.3 %

JANX stock opened at $40.72 on Wednesday. The company has a market capitalization of $2.14 billion, a P/E ratio of -34.80 and a beta of 3.23. The company has a 50-day simple moving average of $53.09 and a 200 day simple moving average of $48.41. Janux Therapeutics has a fifty-two week low of $7.79 and a fifty-two week high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The company’s revenue was down 82.6% compared to the same quarter last year. Equities analysts anticipate that Janux Therapeutics will post -1.38 EPS for the current year.

Insider Buying and Selling

In other Janux Therapeutics news, CEO David Alan Campbell sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total value of $1,005,000.00. Following the sale, the chief executive officer now owns 242,054 shares of the company’s stock, valued at $16,217,618. This trade represents a 5.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Andrew Hollman Meyer sold 13,334 shares of the company’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the transaction, the insider now owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 108,334 shares of company stock worth $6,070,020. Insiders own 29.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of JANX. Janus Henderson Group PLC lifted its position in shares of Janux Therapeutics by 40.0% in the 3rd quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after acquiring an additional 721,563 shares during the period. Logos Global Management LP lifted its position in Janux Therapeutics by 400.0% in the second quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after purchasing an additional 600,000 shares during the period. Point72 Asset Management L.P. boosted its stake in Janux Therapeutics by 190.2% during the third quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock worth $17,985,000 after buying an additional 259,445 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after buying an additional 156,675 shares during the period. Finally, Barclays PLC raised its stake in shares of Janux Therapeutics by 496.5% in the 3rd quarter. Barclays PLC now owns 174,061 shares of the company’s stock valued at $7,907,000 after buying an additional 144,883 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.